8 completed, 3 unknown, 2 not yet recruiting, 2 recruiting. 6 Phase 2, 4 Not applicable, 2 Phase 1, 2 Phase 3.
Follow Cancer of Unknown Primary Site: new trials by email Literature Review of Cancer of Unknown Primary Site trials Research Report on Cancer of Unknown Primary Site
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) F520 combined with chemotherapy, placebo combined with chemotherapy - Cancer of Unknown Primary Site | Phase 2 / Phase 3 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 402 | 2026-07-08 | 2026-08-12 |
| 18F-FAPI PET in Cancers of Unknown Primary Site 18F-FAPI PET - Cancer of Unknown Primary Site | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 120 | 2026-02-01 | 2026-01-28 | |
| The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP) Comprehensive molecular profiling - Cancer of Unknown Primary Site | Not applicable | Not yet recruiting | Haukeland University Hospital | 350 | 2026-01-01 | 2026-01-26 |
| Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary Transoral Ultrasound - Cancer of Unknown Primary Site, Unknown Primary Cancer | Not applicable | Completed | Copenhagen University Hospital, Rigshospitalet | 30 | 2023-02-21 | 2024-05-07 |
| FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary 68Ga-FAPi-46, PET/CT imaging - Cancer of Unknown Primary Site | Not applicable | Unknown | Peter MacCallum Cancer Centre, Australia | 150 | 2022-02-23 | 2023-03-31 |
| Sintilimab in Cancer of Unknown Primary Sintilimab - Cancer of Unknown Primary Site | Phase 2 | Completed | M.D. Anderson Cancer Center | 10 | 2021-08-26 | 2026-02-25 |
| Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China no intervention - Cancer of Unknown Primary Site | Unknown | Fudan University | 200 | 2021-06-18 | 2021-07-07 | |
| Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid Biomarkers Cancer of Unknown Primary Site | Completed | The Christie NHS Foundation Trust | 117 | 2021-06-09 | 2024-10-10 | |
| TCF-001 TRACK (Target Rare Cancer Knowledge) Study FoundationOne CDx and FoundationOne Liquid CDx - Rare Cancers, Cholangiocarcinoma | Not applicable | Recruiting | TargetCancer Foundation | 400 | 2020-10-01 | 2026-05-26 |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography - Bladder Carcinoma, Cervical Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 26 | 2020-08-27 | 2026-02-05 |
| Nivolumab/Ipilimumab in Second Line CUP-syndrome Nivolumab/Ipilimumab - Cancer of Unknown Primary Site | Phase 2 | Unknown | University Hospital Heidelberg | 194 | 2019-12-12 | 2020-04-15 |
| Trial of Pembrolizumab in Cancer of Unknown Primary Pembrolizumab - Cancer of Unknown Primary Site | Phase 2 | Completed | Imperial College London | 35 | 2019-02-22 | 2026-05-04 |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Alectinib, Vismodegib, Ipatasertib - Cancer of Unknown Primary Site | Phase 2 | Completed | Hoffmann-La Roche | 529 | 2018-07-10 | 2025-11-19 |
| Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary tissue-of-origin (ORIGIN-PanCA○R) profiling - Cancer of Unknown Primary Site | Phase 3 | Completed | Fudan University | 182 | 2017-09-18 | 2022-01-24 |
| APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors APL-501 - Solid Tumor, Microsatellite Instability | Phase 1 | Completed | Apollomics (Australia) Pty. Ltd. | 30 | 2017-03-27 | 2022-05-09 |
| Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Teysuno, Capecitabine - Gastrointestinal Cancer, Cancer of Unknown Primary Site | Phase 2 | Completed | University of Edinburgh | 59 | 2014-02-05 | 2023-05-12 |
Neoplasms, Unknown Primary (16) · Cholangiocarcinoma (2) · Adrenal Gland Neoplasms (1) · Bile Duct Neoplasms (1) · Brain Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Gastrointestinal Neoplasms (1) · Hematologic Neoplasms (1) · Microsatellite Instability (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Pancreatic Neoplasms (1)
Neoplasm Metastasis (16) · Neoplastic Processes (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Neoplasms (15) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Carcinoma (3) · Adenocarcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Neoplasms by Site (2) · Adrenal Gland Diseases (1)
FAPI-46 (2) · Bevacizumab (1) · Capecitabine (1) · Carboplatin (1) · Cisplatin (1) · Drug Therapy (1) · Erlotinib Hydrochloride (1) · Fluorodeoxyglucose F18 (1) · Gemcitabine (1) · HhAntag691 (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Paclitaxel (1) · Sequence Analysis, RNA (1)
Fudan University (2) · Apollomics (Australia) Pty. Ltd. (1) · Copenhagen University Hospital, Rigshospitalet (1) · First Affiliated Hospital of Zhejiang University (1) · Haukeland University Hospital (1) · Hoffmann-La Roche (1) · Imperial College London (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Peter MacCallum Cancer Centre, Australia (1) · Shandong New Time Pharmaceutical Co., LTD (1) · TargetCancer Foundation (1) · The Christie NHS Foundation Trust (1) · University Hospital Heidelberg (1) · University of Edinburgh (1)
China (4) · United Kingdom (4) · Australia (3) · United States (3) · Denmark (2) · Germany (2) · Norway (2) · Austria (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Colombia (1) · Croatia (1) · Czechia (1) · Estonia (1)
Harpreet Wasan, MBBS, FRCP (1) · Jeremie Calais (1) · Kanwal Raghav (1) · Marietta Franco (1) · Mina Nikanjam, MD (1) · Razelle Kurzrock, M.D. (1) · Sally Clive, MBChB (1) · Sarah Ngan, MBBS, FRCP (1) · Sheela Rao, MBBS, FRCP (1) · Shumei Kato, M.D. (1) · Tobias Todsen, MD, PhD (1) · Vivek Subbiah, M.D. (1)
PMID 37875494, PMID 39068945, PMID 39096924, PMID 42691436
2017 (1)